Predictions
Moderna Inc.
Start price
Target price
Perf. (%)
€319.25
29.11.21
29.11.21
-
29.11.22
29.11.22
-47.84%
30.11.22
30.11.22
Fair valuation
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
Standard Investments for future growth
Moderna Inc.
Start price
Target price
Perf. (%)
€322.25
29.11.21
29.11.21
-
29.11.25
29.11.25
-69.69%
12.01.24
12.01.24
Top 10 in its market
Could be worthwhile Investment >10% per year
Repligen Corp.
Start price
Target price
Perf. (%)
€264.10
27.11.21
27.11.21
€300.00
31.12.23
31.12.23
-46.31%
08.05.23
08.05.23
Could be worthwhile Investment >10% per year
Bruker Corp.
Start price
Target price
Perf. (%)
€75.50
27.11.21
27.11.21
€100.00
31.12.23
31.12.23
-5.30%
08.05.23
08.05.23
Could be worthwhile Investment >10% per year
Zoom Video Communications Inc
Start price
Target price
Perf. (%)
€201.45
27.11.21
27.11.21
€230.00
31.12.23
31.12.23
-71.40%
08.05.23
08.05.23
Could be worthwhile Investment >10% per year
Zynga Inc.
Start price
Target price
Perf. (%)
€5.74
27.11.21
27.11.21
€4.80
27.11.22
27.11.22
39.69%
14.03.22
14.03.22
Capable Management
Very low/no dividend yield expected
Risky balance sheet
Few uniques
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€152.65
16.11.21
16.11.21
€200.00
31.01.25
31.01.25
36.59%
03.08.22
03.08.22
Could be worthwhile Investment >10% per year
Moderna Inc.
Start price
Target price
Perf. (%)
€199.52
14.11.21
14.11.21
€230.00
14.11.22
14.11.22
-19.81%
18.03.22
18.03.22
Could be worthwhile Investment >10% per year
Zynga Inc.
Start price
Target price
Perf. (%)
€6.55
11.11.21
11.11.21
€7.80
11.11.22
11.11.22
-12.31%
27.11.21
27.11.21
Capable Management
Very low/no dividend yield expected
Risky balance sheet
Few uniques
Bluebird Bio Inc.
Start price
Target price
Perf. (%)
€9.23
09.11.21
09.11.21
€7.00
31.12.23
31.12.23
-56.18%
28.06.22
28.06.22
Could be very worthwhile Investment >20% year
Moderna Inc.
Start price
Target price
Perf. (%)
€193.66
05.11.21
05.11.21
-
05.11.22
05.11.22
3.03%
14.11.21
14.11.21
Risky Investment
Moderna Inc.
Start price
Target price
Perf. (%)
€191.52
05.11.21
05.11.21
-
05.11.22
05.11.22
4.18%
14.11.21
14.11.21
Could be worthwhile Investment >10% per year
Avis Budget Group
Start price
Target price
Perf. (%)
€279.40
02.11.21
02.11.21
-
02.11.22
02.11.22
-21.49%
10.11.21
10.11.21
Probably not worthwhile Investment
Ipg Photonics
Start price
Target price
Perf. (%)
€140.30
01.11.21
01.11.21
€180.00
01.11.22
01.11.22
-38.63%
02.11.22
02.11.22
Could be worthwhile Investment >10% per year
Ipg Photonics
Start price
Target price
Perf. (%)
€140.30
01.11.21
01.11.21
€180.00
01.11.22
01.11.22
-38.63%
02.11.22
02.11.22
Could be worthwhile Investment >10% per year
Zynga Inc.
Start price
Target price
Perf. (%)
€6.30
01.11.21
01.11.21
€5.00
01.11.22
01.11.22
3.92%
11.11.21
11.11.21
Capable Management
Very low/no dividend yield expected
Risky balance sheet
Few uniques
Acceleron Pharma Inc.
Start price
Target price
Perf. (%)
€149.00
30.10.21
30.10.21
€180.00
31.12.23
31.12.23
6.71%
08.05.23
08.05.23
Could be very worthwhile Investment >20% year
Global Blood Therapeutics Inc
Start price
Target price
Perf. (%)
€33.09
30.10.21
30.10.21
€45.00
31.12.23
31.12.23
94.65%
05.08.22
05.08.22
Could be very worthwhile Investment >20% year
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€180.85
16.10.21
16.10.21
€160.00
16.10.22
16.10.22
-6.22%
24.10.21
24.10.21
Could be worthwhile Investment >10% per year
Helmerich & Payne Inc
Start price
Target price
Perf. (%)
€26.92
09.10.21
09.10.21
-
09.10.22
09.10.22
-22.10%
17.12.21
17.12.21
Capable Management
Business model of the past or high risk
Sustainability is little important
iRobot Corp.
Start price
Target price
Perf. (%)
€70.42
09.10.21
09.10.21
-
09.10.22
09.10.22
-28.00%
22.02.22
22.02.22
Some uniques
Differentiated customer and product portfolio
Revenue growth >5% per year expected
Very positive Cash Flow expected
DISH Network Corp. A
Start price
Target price
Perf. (%)
€38.64
01.10.21
01.10.21
-
01.10.22
01.10.22
-52.68%
18.08.22
18.08.22
Higher risks for its business
Very low/no dividend yield expected
Few uniques